questionsmedicales.fr
Bactéries
Proteobacteria
Gammaproteobacteria
Vibrionaceae
Vibrio
Vibrio : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Vibrio
Infections bactériennes
Tests de laboratoire
Vibrio
Tests sérologiques
Vibrio
Traitements
5
Types de Vibrio
Traitement
Complications
5
Infections cutanées
Vibrio
Facteurs de risque
5
Facteurs de risque
Vibrio
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vibrio : Questions médicales les plus fréquentes",
"headline": "Vibrio : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vibrio : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vibrio"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vibrionaceae",
"url": "https://questionsmedicales.fr/mesh/D014737",
"about": {
"@type": "MedicalCondition",
"name": "Vibrionaceae",
"code": {
"@type": "MedicalCode",
"code": "D014737",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio alginolyticus",
"alternateName": "Vibrio alginolyticus",
"url": "https://questionsmedicales.fr/mesh/D044149",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio alginolyticus",
"code": {
"@type": "MedicalCode",
"code": "D044149",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.030"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae",
"alternateName": "Vibrio cholerae",
"url": "https://questionsmedicales.fr/mesh/D014734",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae",
"code": {
"@type": "MedicalCode",
"code": "D014734",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae non-O1",
"alternateName": "Vibrio cholerae non-O1",
"url": "https://questionsmedicales.fr/mesh/D044163",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae non-O1",
"code": {
"@type": "MedicalCode",
"code": "D044163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O1",
"alternateName": "Vibrio cholerae O1",
"url": "https://questionsmedicales.fr/mesh/D041241",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O1",
"code": {
"@type": "MedicalCode",
"code": "D041241",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.151"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O139",
"alternateName": "Vibrio cholerae O139",
"url": "https://questionsmedicales.fr/mesh/D041242",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O139",
"code": {
"@type": "MedicalCode",
"code": "D041242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Vibrio mimicus",
"alternateName": "Vibrio mimicus",
"url": "https://questionsmedicales.fr/mesh/D044164",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio mimicus",
"code": {
"@type": "MedicalCode",
"code": "D044164",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio parahaemolyticus",
"alternateName": "Vibrio parahaemolyticus",
"url": "https://questionsmedicales.fr/mesh/D014736",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio parahaemolyticus",
"code": {
"@type": "MedicalCode",
"code": "D014736",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.590"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio vulnificus",
"alternateName": "Vibrio vulnificus",
"url": "https://questionsmedicales.fr/mesh/D041261",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio vulnificus",
"code": {
"@type": "MedicalCode",
"code": "D041261",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vibrio",
"alternateName": "Vibrio",
"code": {
"@type": "MedicalCode",
"code": "D014733",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jaime Martinez-Urtaza",
"url": "https://questionsmedicales.fr/author/Jaime%20Martinez-Urtaza",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Jessica L Jones",
"url": "https://questionsmedicales.fr/author/Jessica%20L%20Jones",
"affiliation": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136."
}
},
{
"@type": "Person",
"name": "William C Walton",
"url": "https://questionsmedicales.fr/author/William%20C%20Walton",
"affiliation": {
"@type": "Organization",
"name": "2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA."
}
},
{
"@type": "Person",
"name": "Julia C van Kessel",
"url": "https://questionsmedicales.fr/author/Julia%20C%20van%20Kessel",
"affiliation": {
"@type": "Organization",
"name": "Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu."
}
},
{
"@type": "Person",
"name": "Blake Ushijima",
"url": "https://questionsmedicales.fr/author/Blake%20Ushijima",
"affiliation": {
"@type": "Organization",
"name": "Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.",
"datePublished": "2022-10-10",
"url": "https://questionsmedicales.fr/article/35689544",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/cas.15458"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine.",
"datePublished": "2023-01-10",
"url": "https://questionsmedicales.fr/article/36625721",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/08880018.2022.2137609"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pruritic papules after induction chemotherapy with daunorubicin and cytarabine.",
"datePublished": "2022-06-15",
"url": "https://questionsmedicales.fr/article/36259808",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5070/D328357789"
}
},
{
"@type": "ScholarlyArticle",
"name": "Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis.",
"datePublished": "2023-08-28",
"url": "https://questionsmedicales.fr/article/37640495",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ejh.14094"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.",
"datePublished": "2023-08-12",
"url": "https://questionsmedicales.fr/article/37572135",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00277-023-05400-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Bactéries",
"item": "https://questionsmedicales.fr/mesh/D001419"
},
{
"@type": "ListItem",
"position": 3,
"name": "Proteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020560"
},
{
"@type": "ListItem",
"position": 4,
"name": "Gammaproteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020563"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vibrionaceae",
"item": "https://questionsmedicales.fr/mesh/D014737"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vibrio",
"item": "https://questionsmedicales.fr/mesh/D014733"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vibrio - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vibrio",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vibrio",
"description": "Comment diagnostiquer une infection à Vibrio ?\nQuels tests sont utilisés pour identifier Vibrio ?\nLes tests sérologiques sont-ils utiles ?\nPeut-on diagnostiquer Vibrio par PCR ?\nQuels symptômes orientent vers un diagnostic de Vibrio ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Cytarabine#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vibrio",
"description": "Quels sont les symptômes d'une infection à Vibrio ?\nLa diarrhée est-elle toujours présente ?\nLes infections à Vibrio causent-elles de la fièvre ?\nY a-t-il des symptômes graves associés ?\nLes symptômes apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Cytarabine#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vibrio",
"description": "Comment prévenir les infections à Vibrio ?\nLe lavage des mains est-il important ?\nLes vaccinations existent-elles contre Vibrio ?\nFaut-il éviter certains aliments ?\nLes voyages augmentent-ils le risque d'infection ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Cytarabine#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vibrio",
"description": "Quel est le traitement principal pour Vibrio ?\nQuels antibiotiques sont efficaces contre Vibrio ?\nLa réhydratation est-elle toujours nécessaire ?\nLes traitements sont-ils différents selon le type de Vibrio ?\nLes probiotiques aident-ils dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Cytarabine#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vibrio",
"description": "Quelles complications peuvent survenir avec Vibrio ?\nLa déshydratation est-elle une complication fréquente ?\nLes infections à Vibrio peuvent-elles être mortelles ?\nY a-t-il des risques pour les personnes immunodéprimées ?\nLes infections cutanées sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Cytarabine#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vibrio",
"description": "Quels sont les principaux facteurs de risque pour Vibrio ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection ?\nLes personnes vivant près de l'eau sont-elles plus exposées ?\nLes voyages dans des zones endémiques sont-ils risqués ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Cytarabine#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection à Vibrio ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des cultures bactériennes à partir d'échantillons de selles."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour identifier Vibrio ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de culture et des tests biochimiques spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les tests sérologiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sérologiques ne sont généralement pas utilisés pour Vibrio."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer Vibrio par PCR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut être utilisée pour détecter l'ADN de Vibrio dans les échantillons."
}
},
{
"@type": "Question",
"name": "Quels symptômes orientent vers un diagnostic de Vibrio ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes gastro-intestinaux comme la diarrhée aiguë peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection à Vibrio ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre."
}
},
{
"@type": "Question",
"name": "La diarrhée est-elle toujours présente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la diarrhée est fréquente mais pas systématique dans les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio causent-elles de la fièvre ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre peut accompagner les infections à Vibrio, mais ce n'est pas toujours le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes graves associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes graves peuvent inclure déshydratation et choc septique dans les cas sévères."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections à Vibrio ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de consommer des fruits de mer crus ou mal cuits et lavez-vous les mains."
}
},
{
"@type": "Question",
"name": "Le lavage des mains est-il important ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le lavage des mains réduit le risque d'infection par Vibrio et d'autres pathogènes."
}
},
{
"@type": "Question",
"name": "Les vaccinations existent-elles contre Vibrio ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin efficace contre les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains aliments ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, évitez les fruits de mer crus, surtout en période de chaleur ou d'épidémies."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque d'infection ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est endémique augmente le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour Vibrio ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la réhydratation, souvent accompagnée d'antibiotiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels antibiotiques sont efficaces contre Vibrio ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antibiotiques comme la doxycycline et l'azithromycine sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "La réhydratation est-elle toujours nécessaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réhydratation est cruciale, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents selon le type de Vibrio ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement peut varier selon le type de Vibrio et la gravité de l'infection."
}
},
{
"@type": "Question",
"name": "Les probiotiques aident-ils dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les probiotiques peuvent aider à restaurer la flore intestinale, mais ne remplacent pas le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Vibrio ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la déshydratation sévère, le choc septique et l'insuffisance rénale."
}
},
{
"@type": "Question",
"name": "La déshydratation est-elle une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la déshydratation est une complication courante, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio peuvent-elles être mortelles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans les cas graves, les infections à Vibrio peuvent être mortelles sans traitement rapide."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques pour les personnes immunodéprimées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées sont à risque accru de complications graves."
}
},
{
"@type": "Question",
"name": "Les infections cutanées sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Vibrio peut causer des infections cutanées, surtout après des blessures en milieu aquatique."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour Vibrio ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'immunodépression."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru de complications graves liées à Vibrio."
}
},
{
"@type": "Question",
"name": "Le diabète augmente-t-il le risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut augmenter le risque d'infections graves à Vibrio."
}
},
{
"@type": "Question",
"name": "Les personnes vivant près de l'eau sont-elles plus exposées ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être plus exposées aux infections à Vibrio, surtout en été."
}
},
{
"@type": "Question",
"name": "Les voyages dans des zones endémiques sont-ils risqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est courant augmente le risque d'infection."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 30/04/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain.
Publications dans "Vibrio" :
3 publications dans cette catégorie
Affiliations :
U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136.
Publications dans "Vibrio" :
3 publications dans cette catégorie
Affiliations :
2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA.
Publications dans "Vibrio" :
3 publications dans cette catégorie
Affiliations :
Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan, 48513, South Korea.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Department of Food Science and Technology, Pukyong National University, Busan, 48513, South Korea. ymkim@pknu.ac.kr.
Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan, 48513, South Korea. ymkim@pknu.ac.kr.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA payne@utexas.edu.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
International Centre of Excellence for Seafood Safety, Centre for Environment, Fisheries and Aquaculture Science, Weymouth, UK. Electronic address: craig.baker-austin@cefas.co.uk.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Systems, Technological Research Institute, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Department of Bacterial Infections, Research Institute for Microbial Diseases, Osaka University.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
National Center for Food Safety Risk Assessment, Beijing, 100022, China.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA. samoreno@ucf.edu.
National Center for Integrated Coastal Research, University of Central Florida, Orlando, FL, USA. samoreno@ucf.edu.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel. orr@agri.gov.il.
Department of Food Quality and Safety, Agricultural Research Organization, Volcani Center, Rishon LeZion, Israel. orr@agri.gov.il.
Publications dans "Vibrio" :
2 publications dans cette catégorie
Affiliations :
U.S. Food and Drug Administration, Division of Seafood Science and Technology, Gulf Coast Seafood Laboratory, 1 Iberville Drive, Dauphin Island, AL 36528, USA; Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA. Electronic address: vlp0006@auburn.edu.
Publications dans "Vibrio" :
Therapeutic improvements are needed for patients with acute myeloid leukemia (AML), particularly those who have relapsed or who have treatment-refractory (R/R) AML or newly diagnosed patients with poo...
Patients with Langerhans cell histiocytosis (LCH) have been effectively treated with intravenous cytarabine. Intravenous or subcutaneous cytarabine infusions have been effective for leukemia patients,...
We present a 65-year-old woman who developed a diffuse pruritic papular eruption after receiving induction chemotherapy with daunorubicin and cytarabine for newly diagnosed acute myelomonocytic leukem...
The last decade has seen advances in delivering outpatient consolidation therapy for acute myeloid leukemia (AML). The standard of care involves high-dose cytarabine or intermediate-dose cytarabine, g...
This is a retrospective chart review to analyze AML patients treated with outpatient high-dose or intermediate-dose cytarabine consolidation therapy at the London Regional Cancer Program from January ...
Forty-five patients received 89 cycles of cytarabine as outpatients; males were 55.6% of the total population, with a median age of ~57 years. Our overall 2-year survival of HDAC-16 (57.1%) and IDAC-1...
Outpatient administration of intermediate-dose cytarabine once daily over six consecutive days results in similar overall survival and relapse rates as compared to high dose cytarabine consolidation c...
To compare efficacy between homoharringtonine combined with cytarabine and aclarubicin (HAA) and idarubicin and cytarabine (IA) regimens as first induction chemotherapy in patients with core binding f...
Although cytarabine (Ara-C) is the mainstay of treatment for acute myeloid leukemia (AML), its cytotoxic mechanisms for inducing apoptosis are poorly understood. Therefore, we investigated the Ara-C-i...
Despite the approval of several drugs for AML, cytarabine is still widely used as a therapeutic approach. However, 85% of patients show resistance and only 10% overcome the disease. Using RNA-seq and ...
Drug synergy allows reduced dosing, side effects and tolerance. Optimization of drug synergy chemotherapy is fundamental in acute lymphocytic leukemia and other cancers. This study aimed to analyze th...
Mantle cell lymphoma is considered an aggressive B-cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction...
Herein, we performed a retrospective analysis of the clinical characteristics of 10 patients who received induction treatment consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and p...
Although one patient discontinued R-BAC therapy due to a rash, the other nine completed the scheduled chemotherapy. All patients achieved complete response, underwent high-dose chemotherapy and autolo...
R-CHOP/R-BAC may be a good induction therapy for transplant-eligible patients with mantle cell lymphoma....
We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leuk...
We included 87 patients with newly diagnosed acute myeloid leukemia and a t(15;17) or promyelocytic leukemia/retinoic acid receptor alpha (PML-RARα) mutation. Patients received 12 mg/m2/day idarubicin...
The CR, 10-year RFS, and 10-year OS rates were 89.7%, 94.1%, and 73.8%, respectively, for all patients. The 10-year OS rate was 100% for patients that achieved CR. Subjects were classified according t...
Adding cytarabine to anthracycline plus ATRA was not inferior to anthracycline plus ATRA alone, but it was not comparable to arsenic trioxide plus ATRA. The probability of secondary malignancy was low...